PfizerBOM:500680 -0.92%73 EBITDA Margin % is 45.41% as of Mar. 2026, which is 29% above its 10-year median of 35.32. GuruFocus rates BOM:500680 with a GF Score™ of 73/100 and a GF Value™ of ₹4,882.77 (Fairly Valued). Among 952 Drug Manufacturers companies, Pfizer ranks better than 94.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pfizer's EBITDA for the
three
months ended in Mar. 2026 was ₹2,857 Mil. Pfizer's Revenue for the
three
months ended in Mar. 2026 was ₹6,292 Mil. Therefore, Pfizer's EBITDA margin for the quarter that ended in Mar. 2026 was 45.41%.
Pfizer (BOM:500680) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pfizer EBITDA Margin % Related Terms
Pfizer EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pfizer's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500680 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Pfizer's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pfizer's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pfizer's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer (BOM:500680) has a EBITDA Margin % of 45.41% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pfizer and its competitors. This is 29% above median its historical median of 35.32. Over the past decade, Pfizer's EBITDA Margin % has ranged from 29.54 to 47.57. According to the industry distribution chart, Pfizer ranks #53 out of 952 companies in the Drug Manufacturers industry, placing it in the top 5.6%.
Is Pfizer's EBITDA Margin % too high?
Pfizer's current EBITDA Margin % of 45.41% is 29% above median its 10-year median of 35.32. Over the past 10 years, this metric has ranged from a low of 29.54 to a high of 47.57. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Pfizer's value of 45.41% is 264.2% above this industry median. Based on the distribution chart, Pfizer ranks #53 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pfizer has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pfizer ranks #53 out of 952 companies for EBITDA Margin %. This places Pfizer in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Pfizer's value of 45.41% is 264.2% above this benchmark. Historically, Pfizer's own EBITDA Margin % has ranged from 29.54 to 47.57 over the past decade. While the company's 10-year median is 35.32 vs. the industry median of 12.47, Pfizer has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pfizer's current EBITDA Margin % of 45.41% is 264.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pfizer and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pfizer's current EBITDA Margin % is 45.41%, which is 29% above median its own 10-year median of 35.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (BOM:500680) is currently considered Fairly Valued. The stock's GF Value™ is ₹4,882.77, compared to a current price of ₹4,465.70 — trading 8.5% below its estimated fair value. The current EBITDA Margin % is 45.41%, which is 29% above median its 10-year median of 35.32 and 264.2% above the Drug Manufacturers industry median of 12.47. Pfizer's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pfizer (BOM:500680), the current EBITDA Margin % is 45.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pfizer (BOM:500680) Overvalued in 2026?
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued.
The current stock price of ₹4,465.70 is trading 8.5% below its estimated GF Value™ of ₹4,882.77.
GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for BOM:500680:
EBITDA Margin %: 45.41% (29% above median its 10-year median of 35.32)
GF Value™: ₹4,882.77 vs. price of ₹4,465.70 (8.5% below fair value)
Industry Position: 264.2% above the Drug Manufacturers median (#53 of 952)
No single metric tells the full story. See the BOM:500680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The company has only one segment which is Pharmaceuticals and it operates in domestic market.
73GF Score
Get the complete analysis for BOM:500680
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500680 has been successfully added to your 
